Analytical Data
-
Gene name
Allergen Fel d 4
- Application
-
Alternative Names
Allergen Fel d 4; allergen Fel d 4
-
Species
Cat
-
Source
E. coli
-
Tag
N-His;N-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5VFH6
-
Expression Region
H16-E186
-
Protein Length
Full Length of Mature Protein
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fel d 4 is a major allergen derived from domestic cats, belonging to the lipocalin protein family. It is known to be a significant trigger for allergic reactions in sensitized individuals, contributing to symptoms such as asthma, rhinitis, and conjunctivitis. The prevalence of cat allergies has been rising, affecting millions of people worldwide and resulting in a significant public health concern. Research into Fel d 4 is crucial, as it provides insights into the molecular mechanisms of allergic responses and can facilitate the development of targeted immunotherapies. Recombinant Fel d 4 protein has been produced to study its structure, function, and allergenic properties in a controlled environment, allowing for the advancement of allergen-specific therapies. This approach aims to reduce sensitivity in allergic individuals and improve their quality of life. Additionally, understanding the potential cross-reactivity of Fel d 4 with other allergens may help in developing broader strategies for managing allergies. The ongoing research into Fel d 4's role in allergic mechanisms is essential for designing effective interventions and treatments for cat allergies, potentially leading to new avenues in allergy management.
